SCHEDULE 13G/A Filing for Haemonetics Corp by Vanguard Group Inc

This filing is an amendment to a previous filing by Vanguard Group Inc. regarding Haemonetics Corp. The filing indicates that Vanguard Group, including its subsidiaries and managed accounts, has the right to receive or direct the receipt of dividends and proceeds from the sale of securities. No single person or entity holds more than 5% interest in the reported securities. The filing also notes an internal realignment within Vanguard Group as of January 12, 2026, leading to separate reporting of beneficial ownership by certain subsidiaries and business divisions. This realignment is in accordance with SEC Release No. 34-39538.